tbuckley/cabot-search huggingface dataset:
THE EFFECT OF OVERSIZING ON THE HEMODYNAMIC PERFORMANCE OF THE SAPIEN 3 TRANSCATHETER HEART VALVE
Authors: Rebecca T. Hahn, Brendan Fox, Omar Khalique, Nadira Hamid, Mathew Williams, Isaac George, Tamim Nazif, Torsten Vahl, Hemal Gada, Jonathon White, Puja Parikh, Martin Leon, Susheel Kodali
Journal: Journal of the American College of Cardiology (2015)
Ectopic varices in a pancreatojejunal anastomosis: a rare cause of hemorrhage
Authors: Bruno Gonçalves, Pedro Bastos, Pedro Leão, Carla Rolanda
Journal: Endoscopy (2015)

Ectopic variceal bleeding is a rare cause of gastrointestinal hemorrhage, representing up to 5 % of all variceal bleeding episodes [1]. The most common cause of ectopic variceal bleeding is portal hypertension (from both intrahepatic and extrahepatic causes) [2]. In the absence of portal hypertension, other causes may include abdominal surgery, abnormalities in the venous outflow vessels, abdominal vascular thrombosis, hepatocellular carcinoma, pancreatitis, and familial syndromes [2] [3]. Ectopic variceal bleeding can pose a diagnostic dilemma and endoscopy plays a major role in the diagnosis and treatment of this condition.
The Breast Journal
Authors: Gilda Cardenosa
Journal: JAMA (1997)

Why a new journal? The editor answers that<i>The Breast Journal</i>is "designed to provide the first comprehensive, multidisciplinary source devoted exclusively to all facets of research, diagnosis, and treatment of breast disease." The editor outlines how the magnitude of breast cancer led to the model of multidisciplinary breast health centers and proposes a similar medical literature structure to address all areas of breast disease, including pain management, psychological support, prevention, recovery from surgery and chemotherapy, prostheses, and management of terminal illness. The first three issues reflect this multidisciplinary approach, with articles of interest to the radiologist, surgeon, oncologist, pathologist, psychologist, and primary care physician. Readers ae treated to intriguing editorials such as the emerging importance of molecular
PTU-036 Endoscopic Management of Malignant Gastric Outlet Obstruction: Results from a Newly Created Regional Cancer Service
Authors: D Ismail, J Deacon, B Macfarlane, D L Morris, M Fullard, I Sargeant, J Evans, A Leahy
Journal: Gut (2013)

<h3>Introduction</h3> Malignant gastric outlet obstruction can be a distressing medical condition leading to considerable morbidity with a well recognised poor prognosis. Previous studies (mostly outside of the UK) have shown that endoscopic insertion of a duodenal stent can alleviate the obstructive symptoms to good effect (1–3). In 2009, we set up a regional service for duodenal stent insertion with an aim to replicate these results across a UK upper gastro-intestinal cancer network (catchment area 1.4 million). <h3>Methods</h3> A retrospective analysis was performed in patients who had an endoscopically placed duodenal stent for inoperable cancer causing mechanical gastric outlet obstruction. We reviewed hospital/endoscopy electronic records regarding patient demographics, length of hospital stay after the procedure, endoscopy re-intervention and survival. <h3>Results</h3> Between July 2009 and November 2012 a total of 27 patients underwent duodenal stent (uncovered WallFlex®, Boston Scientific) insertion. 15 were men, mean age of 70.6 years (range 27–86). 23/27 (85%) patients were discharged home after the procedure, 2 were transferred to a hospice and 2 died in hospital. The average length of hospital stay after the procedure was 5.7 days (range 0–25). Endoscopy re-intervention was performed in 2 patients for stent occlusion requiring further stent insertion. 22 patients have been followed until death with a mean survival period of 12.5 weeks (range 1–34). 5 patients remain alive at the time of abstract submission. <h3>Conclusion</h3> Duodenal stent insertion offered a good palliative option in most of our patients. Our patient outcomes compared favourably to previous published studies. <h3>Disclosure of Interest</h3> None Declared <h3>References</h3> ASGE Technology Committee. The role of endoscopy in gastroduodenal obstruction and gastroparesis. Gastrointest Endosc 2011; 74(1):13–21. Sasaki T, Isayama H, Maetani I <i>et al.</i> Japanese multicenter estimation of wallflex duodenal stent for unresectable malignant gastric outlet obstruction Dig Endosc 2013 25(1):1–6. Costamagna G, Tringali A, Spicak J <i>et al.</i> Treatment of malignant gastroduodenal obstruction with a nitinol self-expanding metal stent: an international prospective multicentre registry. Dig Liver Dis 2012 44(1):37–43.
In vitro assay of cytotoxicity with cultured liver: accomplishments and possibilities.
Authors: J W Grisham, R K Charlton, D G Kaufman
Journal: Environmental Health Perspectives (1978)

Tissue cultures offer potential advantages for assaying the toxicity of chemicals and for evaluating tissue susceptibility to toxic agents. Several properties of cultured cells hinder the immediate, widespread use of tissue cultures to assay toxicity routinely. These points are illustrated by briefly reviewing attempts to utilize different types of hepatic cultures to evaluate the actions of carcinogenic chemicals in vitro. Hepatocytes in vivo apparently can metabolize all known procarcinogenic chemicals, but the process of tissue isolation and the environmental conditions in vitro may modify drastically the responses of hepatocytes and other cultured hepatic cells to toxic chemicals. Before cell cultures can be used routinely as the basis of screening systems to detect chemical toxins, specificity and sensitivity of response to chemicals representing all chemical classes must be validated by laboratory studies.
Molecular Analysis of the Short Arm of Chromosome 3 in Small-Cell and Non-Small-Cell Carcinoma of the Lung
Authors: H Brauch, B Johnson, J Hovis, T Yano, A Gazdar, O S Pettengill, S Graziano, G D Sorenson, B J Poiesz, J Minna
Journal: New England Journal of Medicine (1987)

Previous studies have suggested that the loss of DNA sequences on the short arm of chromosome 3 (3p) is associated with small-cell lung carcinoma. We therefore looked for loss of 3p alleles in tumor tissue from 42 patients with either small-cell or non-small-cell lung carcinoma. All 13 patients with small-cell lung carcinoma who were heterozygous for one or more alleles at 3p in normal tissue had the loss of at least one codominant allele in the tumor tissue. Cell lines of small-cell lung carcinoma from an additional eight patients were homozygous for 3p alleles; this result was significantly different from the predicted frequency of homozygosity. The tumor tissue studied included cell lines of small-cell lung carcinoma obtained from biopsy specimens, an autopsy sample, and an excised lymph node containing tumor cells. Loss of alleles at 3p was observed in tumor samples obtained before and after chemotherapy. Four of 15 evaluable patients with non-small-cell carcinoma of the lung had loss of 3p alleles. We conclude that loss of alleles at 3p is a change found consistently in small-cell lung carcinoma and occasionally in non-small-cell lung carcinoma.
RAC Approves Gene Protocol For Adult Twins With AIDS
Authors: S. Jenks
Journal: JNCI Journal of the National Cancer Institute (1992)

Journal Article RAC Approves Gene Protocol For Adult Twins With AIDS Get access Susan Jenks Susan Jenks Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 84, Issue 19, 7 October 1992, Pages 1468–1469, https://doi.org/10.1093/jnci/84.19.1468 Published: 07 October 1992
AB0395 Evaluation of the organ damage detected by systemic lupus international collaborating clinics/american college of rheumatology (slicc/acr) damage index. a monocentric cross-sectional study on 349 patients affected by systemic lupus erythematosus.
Authors: F. Ceccarelli, L. Massaro, C. Perricone, I. Leccese, S. Truglia, F. Miranda, V. A. Pacucci, E. Cipriano, F. Martinelli, F. R. Spinelli, C. Alessandri, F. Conti, G. Valesini
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> The survival and outcome of patients affected by Systemic Lupus Erythematosus (SLE) have improved dramatically over the past 50 years in terms of mortality and morbidity rates. However, the activity of disease and the long-term therapy could be associated with the development of a chronic damage <h3>Objectives</h3> To evaluate organ damage using SLICC/ACR damage index (SDI) in a large monocentric and well-characterized cohort of patients affected by SLE and to investigate its correlation with clinical, demographic and laboratory features. <h3>Methods</h3> Consecutive patients affected by SLE (revised ACR criteria) referring to a Lupus Clinic, were enrolled to perform a cross-sectional analysis. At each visit, the patients underwent complete physical examination, and the clinical and laboratory data were collected in a standardized computerized electronically-filled form. Chronic damage was evaluated in all the patients by using SDI. <h3>Results</h3> In our study, 349 SLE patients (M/F 25/324; mean age at the onset ± SD 29.2±12 years, mean age ± SD 42.7±12.4 years, mean disease duration ± SD 164.9±105.2 months) were enrolled. A SDI value ≥ 1 was observed in 125 patients (35.8%), with a mean SDI value of 1.7±0.9 (range 1-5). Patients with SDI ≥ 1 showed significant higher mean values of age (38.8±11.3 <i>vs</i> 49.7±11.3) and disease duration (135.6±93.1 <i>vs</i> 217.5±105.4) compared with patients without chronic damage. Musculoskeletal was the system most frequently involved (41 patients, 33%), followed by neuropsychiatric manifestations and malignancies, both registered on 24 patients (19%) and the renal involvement (19 pts,15%). Interestingly, neuropsychiatric manifestations were significantly associated with the presence of anticardiolipin antibodies (P=0.0005) and the occurrence of thrombotic events (P=0.0006). Moreover, regarding the development of malignancies, the most frequently types detected in the present cohort were thyroid and mammalian carcinoma (29.2% and 20.8% respectively), according with the higher incidence of disease in female subjects. <h3>Conclusions</h3> A mild chronic damage, significantly associated with age and disease duration, involving primarily musculoskeletal system, was detected in the present monocentric, large cohort of SLE patients. Moreover, the role of anticardiolipin antibodies in the neuropsychiatric manifestations was underlined. These results confirm that the tight monitoring and the new available therapeutical options allow a better long-time control of disease, with consequent survival improvement. <h3>Disclosure of Interest</h3> None Declared
Successful Treatment of Cerebral Herniation in Five Patients
Authors: Nicholas T. Zervas, John Hedley-Whyte
Journal: New England Journal of Medicine (1972)

Five patients had decerebration secondary to intracranial hemorrhage. In two intracerebral bleeding was caused by ruptured cerebral aneurysms, in three by trauma. Preoperative treatment consisted of endotracheal intubation followed by hyperventilation; mannitol was also given. Four patients received dexamethasone. Reduction in the size of the dilated pupils and cessation of decerebrate posturing were noted in the two patients with aneurysms before operative evacuation of the hematoma. Blood gas analysis before operation, but after medical decompression with mannitol and dexamethasone, demonstrated arterial carbon dioxide tensions ranging from 26 to 46 mm of mercury (average, 36 mm), and arterial pH from 7.30 to 7.51 (average, 7.42). After operation, when hematoma had been evacuated, decerebrate rigidity was absent, and anisocoria was improved. All patients were fully conscious within two to 26 hours and ultimately regained normal intellectual and psychologic function.
A unique<i>LAMB3</i>splice-site mutation with founder effect from the Balkans causes lethal epidermolysis bullosa in several European countries
Authors: B. Mayer, P. Silló, M. Mazán, D. Pintér, M. Medvecz, C. Has, D. Castiglia, F. Petit, A. Charlesworth, Zs. Hatvani, H. Pamjav, S. Kárpáti
Journal: British Journal of Dermatology (2016)

We have encountered repeated cases of recessive lethal generalized severe (Herlitz-type) junctional epidermolysis bullosa (JEB gen sev) in infants born to Hungarian Roma parents residing in a small region of Hungary.To identify the disease-causing mutation and to investigate the genetic background of its unique carrier group.The LAMB3 gene was analysed in peripheral-blood genomic DNA samples, and the pathological consequences of the lethal defect were confirmed by cutaneous LAMB3cDNA sequencing. A median joining haplotype network within the Y chromosome H1a-M82 haplogroup of individuals from the community was constructed, and LAMB3 single-nucleotide polymorphism (SNP) patterns were also determined.An unconventional intronic splice-site mutation (LAMB3, c.1133-22G>A) was identified. Thirty of 64 voluntarily screened Roma from the closed community carried the mutation, but none of the 306 Roma from other regions of the country did. The age of the mutation was estimated to be 548 ± 222 years. Within the last year, more patients with JEB gen sev carrying the same unusual mutation have been identified in three unrelated families, all immigrants from the Balkans. Two were compound heterozygous newborns, in Germany and Italy, and one homozygous newborn died in France. Only the French family recognized their Roma background. LAMB3SNP haplotyping confirmed the link between the apparently unrelated Hungarian, German and Italian male cases, but could not verify the same background in the female newborn from France.The estimated age of the mutation corresponds to the time period when Roma were wandering in the Balkans.
Abstract 3640: Discovery of quinazolinones as fibroblast growth factor receptor (FGFR1-4) kinase inhibitors
Authors: Olivier Querolle, Patrick Angibaud, Hélène Colombel, Virginie Caron, Isabelle Pilatte, Virginie Poncelet, Norbert Esser, Ron Gilissen, Peter King, Lieven Meerpoel, Tinne Verhulst, Berthold Wroblowski, Jorge Vialard, Chris W. Murray, David C. Rees, Anita Reningovolo, Gordon Saxty
Journal: Cancer Research (2015)

Abstract Recent data obtained in several tumor types have identified Fibroblast Growth Factor signaling as a key factor in the molecular pathology of a number of cancers1. This has stimulated the development of a number of agents that block this pathway, including FGFR kinase inhibitors with diverse inhibition and pharmacological profiles that are currently being evaluated in clinical studies. We recently reported that a quinoxaline moiety can efficiently bind the hinge region of FGFR kinase catalytic sites. In continuation of our efforts to discover additional FGFR1-4 inhibitors, we have identified a quinazolinone scaffold as a novel FGFR kinase hinge binder. Initial hits were optimized into compounds displaying nanomolar affinity for FGFR1-4, potent activity in FGFR driven cells and efficacy in a Ba/F3-FGFR3 xenograft model. This report represents the first disclosure of the structure-activity relationships as well as the chemical synthesis pathways of these novel quinazolinone-based FGFR1-4 inhibitors. Turner N. and Grose R. Nature Reviews-Cancer 2010, 10, 116-129 Citation Format: Olivier Querolle, Patrick Angibaud, Hélène Colombel, Virginie Caron, Isabelle Pilatte, Virginie Poncelet, Norbert Esser, Ron Gilissen, Peter King, Lieven Meerpoel, Tinne Verhulst, Berthold Wroblowski, Jorge Vialard, Chris W. Murray, David C. Rees, Anita Reningovolo, Gordon Saxty. Discovery of quinazolinones as fibroblast growth factor receptor (FGFR1-4) kinase inhibitors. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 3640. doi:10.1158/1538-7445.AM2015-3640
Prospective Evaluation of Serum HER2 and HER2 Expression on Circulating Tumor Cells in Patients with Metastatic Breast Cancer within the DETECT Study.
Authors: V. Mueller, S. Riethdorf, B. Rack, W. Janni, P. Fasching, K. Pantel, G. Gebauser, E. Solomayer, B. Aktas, S. Kasemier-Bauer, T. Fehm
Journal: Cancer Research (2009)

Abstract Background: Assessment of HER2 status at the time of metastatic disease might help to optimize treatment decisions in patients with no HER2 status determined at first diagnosis and could also be helpful since HER2 status may change during disease progression. In this context, determination of serum HER2 or the evaluation of HER2 status on circulating tumor cells (CTC) is of potential relevance especially for optimizing HER2-directed therapy. The aim of this study was therefore to determine the serum HER2 status and the HER2 status of CTC from corresponding patients.Methods: Blood samples were obtained in a prospective multicenter setting from 251 patients with metastatic breast cancer at the time of disease progression. Serum HER2 was determined using the commercial HER2 ELISA-kit (Oncogene Science). CTC were detected and HER2 expression was assessed with the CellSearch™ system (Veridex).Results: 119 of 251 (47%) metastatic patients had elevated serum HER2 levels above 15 ng/mL. Serum HER2 was elevated in 49 (66%) of 74 patients with HER2 positive primary tumors, in 57 of 148 (39%) with HER2 negative primary tumors and in 13 of 29 (45%) patients with unknown HER2 primary tumor status. CTC were detected in 133 of 243 evaluable patients (5 or more cells), in these HER2 overexpression on CTC (strong overexpression in at least one cell) was detected in 52 cases (39%). Only 20 of these patients had a HER2 positive primary tumor. In patients with HER2 positive CTC, serum levels were above the cut off in 34 of 52 (65%), while in those with HER2 negative CTC 44 of 81 (54%) showed elevated HER2 serum levels. Concordance between HER2 status of circulating tumor cells and elevated serum HER2 was seen in 71 of 133 patients (53%).Conclusions: Our study demonstrates with a prospective design that also in patients with initially negative HER2 tumor status elevated serum HER2 levels and/or HER2 positive CTC can be detected at the time of metastatic disease. This is of clinical relevance since these patients in current practice do not have access to HER2 targeted therapy. Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 3050.
Loss of Peristaltic Reserve, Determined by Multiple Rapid Swallows, Is the Most Frequent Esophageal Motility Abnormality in Patients With Systemic Sclerosis
Authors: Dustin A. Carlson, Michael D. Crowell, Jessica N. Kimmel, Amit Patel, C. Prakash Gyawali, Monique Hinchcliff, W. Leroy Griffing, John E. Pandolfino, Marcelo F. Vela
Journal: Clinical Gastroenterology and Hepatology (2016)
Case 3-2013
Authors: David J.R. Steele, Anne G. Kasmar, Alexander R. Guimaraes, John P. Dekker
Journal: New England Journal of Medicine (2013)

A 72-year-old woman from Southeast Asia with end-stage renal disease was admitted to the hospital with abdominal pain and vomiting. She had been receiving peritoneal dialysis, reportedly had had multiple episodes of peritonitis, and had recently switched to hemodialysis.
A “datathon” model to support cross-disciplinary collaboration
Authors: Jerôme Aboab, Leo Anthony Celi, Peter Charlton, Mengling Feng, Mohammad Ghassemi, Dominic C. Marshall, Louis Mayaud, Tristan Naumann, Ned McCague, Kenneth E. Paik, Tom J. Pollard, Matthieu Resche-Rigon, Justin D. Salciccioli, David J. Stone
Journal: Science Translational Medicine (2016)

In recent years, there has been a growing focus on the unreliability of published biomedical and clinical research. To introduce effective new scientific contributors to the culture of health care, we propose a "datathon" or "hackathon" model in which participants with disparate, but potentially synergistic and complementary, knowledge and skills effectively combine to address questions faced by clinicians. The continuous peer review intrinsically provided by follow-up datathons, which take up prior uncompleted projects, might produce more reliable research, either by providing a different perspective on the study design and methodology or by replication of prior analyses.
GW25-e2496 In Vivo Detection of Macrophages and Observing the Effect of Atorvastatin on Vulnerable Atherosclerotic Plaque using USPIO-enhanced Magnetic Resonance Imaging in Rabbits
Authors: Qi Chunmei, Deng Liangrong, Li Dongye, Wu Weiheng, Zhang Tao, Zhang Yu
Journal: Journal of the American College of Cardiology (2014)
Abstract 2892: Enhancing anti cancer activity of PI103, a dual PI3K/mTOR inhibitor, by designing a self assembled Nanoformulation
Authors: Bhaskar Roy, Poulomi Sengupta, Shivani Soni, Anne Laure Papa, Jawahar Kopparam, Sasmit Sarangi, Ambarish Pandey, Sudipta Basu, Shiladitya Sengupta
Journal: Cancer Research (2012)

Abstract The phosphoinositide 3-kinase (PI3K)/ mammalian target of rapamycin (mTOR) pathway plays a pivotal role in the growth and survival of various cancers. Small molecule inhibitors targeting PI3K/AKT/mTOR pathway (eg. Wortmannin, LY294002, PI-103, PI828) are promising anti cancer agents. Major drawbacks of these drugs are their poor water solubility and off-target toxicity. Nanoscale drug delivery systems have been harnessed as drug carriers to target tumours through enhanced permeation and retention effect. In this study, we developed a nanoformulation of PI103, a potent dual PI3K/mTOR inhibitor, to improve delivery and reduce side effects. PI103 was encapsulated in a homogeneous self-assembled mixture of phosphatidylcholine and cholesterol. DSPE-PEG protective shell was introduced to increase its circulation time. Thin-film-hydration technique followed by extrusion through 200 nm porous membranes developed nanoparticles of 110-150 nm size with 0.15-0.20 mM drug loading. Release kinetics study confirmed the stability of this formulation in PBS for several days as well as a sustained release property in in-vitro Cell Lysate system. In-vitro cell proliferation assay demonstrated improved cytotoxicity of nanoformulated PI103 in murine breast cancer cell line 4T1 and K-ras upregulated and PTEN suppressed ovarian cancer model cells. Fluorescent Activated Cell Sorting (FACS) analysis with FITC tagged Annexin-V, an early apoptosis marker, showed increased apoptosis with the nanoformulation than the free drug. Western blot analysis expressed more potent inhibition of PI3 kinase/Akt pathway by the nanoformulated PI103. These results indicate that nanoformulation can enhance the potential of PI103. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 2892. doi:1538-7445.AM2012-2892
Case 20-2007
Authors: Michael J. Cunningham, Derrick T. Lin, William T. Curry, David H. Ebb, Torunn I. Yock, Hugh D. Curtin, William C. Faquin
Journal: New England Journal of Medicine (2007)

An 11-year-old boy was seen because of a calcified mass in the ethmoid sinus and nose. He had a 5-year history of nasal congestion and headaches; 2 months before presentation, physical examination disclosed a mass in the right naris, and imaging studies showed a calcified mass that appeared to arise in the ethmoid sinus.
Diagnosis of Orbital Cavernous Hemangioma With Tc-99m RBC SPECT
Authors: W W Ki, J W Shin, K S Won, J S Ryu, S O Yang, H K Lee, Y J Kim
Journal: Clinical Nuclear Medicine (1997)

The authors report two cases of orbital cavernous hemangioma diagnosed by Tc-99m RBC SPECT. Tc-99m RBC SPECT showed a typical scintigraphic pattern commonly seen in hepatic hemangioma in which there is intense focally increased uptake on delayed SPECT images. Tc-99m RBC SPECT in orbital cavernous hemangioma may be as useful a diagnostic modality as in hepatic hemangioma.